Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Forward Printable StoryPrint Comment




Cardiology Homepage

Boston Scientific receives FDA approval for LOTUS Edge Aortic Valve System

FDA grants first-ever clearances to detect bradycardia and tachycardia on a personal ECG device

Indegene AI-driven next generation commercialization platform launches Yosprala

Leading vascular surgeon presents comparative data analysis on EndoAVF procedures at Society of Interventional Radiology 2019

Intact Vascular’s Tack Endovascular System receives FDA approval

iSchemaView’s RAPID approved for use in the Kingdom of Saudi Arabia

Stryker launches LIFEPAK CR2 defibrillator with LIFELINKcentral AED program manager in the United States

Avinger (AVGR) announces receipt of FDA 510(k) clearance of Pantheris SV device

BIOTRONIK launches PK Papyrus covered coronary stent in the US

Insera earns CE Mark approval for cyclical-suction stroke thrombectomy platform, the CLEAR aspiration system

Preliminary in vitro data on Anaconda Biomed’s advanced thrombectomy system presented at ABC WIN 2019

Press releases may be edited for formatting or style
BARCELONA, Spain--(BUSINESS WIRE)--Anaconda Biomed, a medical technology company developing next generation thrombectomy systems for the treatment of ischemic stroke, has announced that preliminary in vitro data on its Advanced Thrombectomy System were unveiled at the 39th ABC-WIN meeting in Val d’Isère, France. Presented by Dr. Tommy Andersson, Professor of Neurointervention, AZ Groeninge, Kortrijk, Belgium and Senior Consultant in Neurointervention, Department of Neuroradiology, Karolinska University Hospital, Stockholm, the data showed that reperfusion rates with the Advanced Thrombectomy System significantly outperformed competing mechanical thrombectomy devices at first pass and after three passes.

“Mechanical thrombectomy techniques and devices have improved significantly over the years, but limitations remain. These range from difficulties with distal blood flow arrest and clot fragmentation to no or low reperfusion at first pass,” said Dr. Andersson. “In the in vitro model, with the Advanced Thrombectomy System, operators were able to overcome these challenges. Assuming these results can be replicated clinically, I believe this system has tremendous potential for fast, effective yet safe endovascular treatment of patients suffering from a major stroke.”

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

Anaconda’s Advanced Thrombectomy System consists of a delivery catheter, a unique, funnel-shaped aspiration catheter and a stent retriever. When deployed, the funnel self-expands and directly conforms to the artery diameter up to 5mm, locally arresting flow and allowing full thrombus extraction without fragmentation.

The in vitro study compared the use of the Advanced Thrombectomy System in conjunction with a stent retriever (Solitaire, Medtronic) to a balloon-guide catheter with a stent retriever (BGC + Solitaire), and to an intermediate distal access catheter with a stent retriever (DAC + Solitaire).

The study results demonstrated that, as compared to the other device combinations, the Advanced Thrombectomy System achieved statistically significant improvement in revascularization rates at both first and third pass. In fact, using the system, operators were able to achieve complete recanalization [Thrombolysis in Cerebral Infarction (TICI) grade of 2b/3] in 100 percent of the cases with an average of only 1.06 passes. Operators also found that the system’s unique design enabled complete local flow restriction and allowed for a safe exit.

“Our mission at Anaconda is to deliver next generation technology that can dramatically accelerate and improve endovascular treatment of major ischemic stroke patients so that death and disability are reduced to the minimum,” said Francois Salmon, CEO of Anaconda Biomed. “We are gratified by this preliminary in vitro data and look forward to continued study of our system.”

About Anaconda Biomed
Anaconda Biomed is a medical technology company dedicated to developing next generation thrombectomy systems for the treatment of ischemic stroke. Its flagship product is the Advanced Thrombectomy System.

Cardiology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.